Head-To-Head Review: DIAGNOS (OTCMKTS:DGNOF) & OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX) and DIAGNOS (OTCMKTS:DGNOF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

76.5% of OptimizeRx shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares OptimizeRx and DIAGNOS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.52%	7.03%
DIAGNOS	-7,014.89%	N/A	-192.10%

Risk & Volatility

OptimizeRx has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, DIAGNOS has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for OptimizeRx and DIAGNOS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1	2	6	0	2.56
DIAGNOS	0	0	0	0	0.00

OptimizeRx presently has a consensus target price of $11.43, suggesting a potential upside of 27.54%. Given OptimizeRx’s stronger consensus rating and higher possible upside, equities research analysts plainly believe OptimizeRx is more favorable than DIAGNOS.

Valuation & Earnings

This table compares OptimizeRx and DIAGNOS”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43 million	1.54	$5.13 million	$0.35	25.60
DIAGNOS	$50,000.00	694.53	-$3.30 million	($0.04)	-7.17

OptimizeRx has higher revenue and earnings than DIAGNOS. DIAGNOS is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Summary

OptimizeRx beats DIAGNOS on 13 of the 14 factors compared between the two stocks.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About DIAGNOS

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.